An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
about
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsAdvances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotideIrritable bowel syndrome: a concise review of current treatment conceptsResponders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-CPlacebo effect in clinical trial design for irritable bowel syndromeEffect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.Effective Constipation Treatment Changes More Than Bowel Frequency: A Systematic Review and Meta-Analysis.Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide.
P2860
Q26748617-22160330-7AE0-4B2A-8A77-3D76396F7BEAQ26865304-73CABA35-E96D-4946-9E34-D21BDB1CAC67Q26996547-824948B0-BD7B-4EE2-A9BF-77B56CE2661BQ30724990-BF3963B6-728B-4FD6-8DEF-0180C025F320Q33586880-CE6A37DA-FE5B-45D6-9BA8-B93F995576A4Q34392861-E688EAEC-C3C7-443C-A157-6FD2A29E59C5Q35655989-C4BF4781-E090-4B92-B3B0-D3F07CB6062CQ36426025-6F0212CC-A1E0-41F8-B505-58F47BC8904EQ38194631-B1AECF60-F8ED-4797-B912-0EBBFE9408D9Q43358725-957236C6-BF5B-470F-9509-D10338E3F3C7Q45842056-B74D1F3F-528A-4779-8B9C-F06C8B655C75
P2860
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@ast
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@en
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@nl
type
label
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@ast
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@en
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@nl
prefLabel
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@ast
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@en
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@nl
P2093
P2860
P356
P1476
An evaluation of the FDA respo ...... otide Phase 3 clinical trials.
@en
P2093
B J Lavins
J E Macdougall
J M Johnston
L M Nelson
M G Currie
R T Carson
P2860
P304
P356
10.1111/NMO.12089
P577
2013-02-06T00:00:00Z